RedHill Biopharma Ltd., a biopharmaceutical company, received a notification from the United States Securities and Exchange Commission (SEC) on February 14, 2024, regarding its Registration Statement on Form F-1, which was filed on February 9, 2024. The SEC informed the company that it has not reviewed and will not review the registration statement. The SEC's communication reminded RedHill Biopharma of its responsibility for the accuracy and adequacy of the disclosures in the registration statement. The SEC also pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. RedHill Biopharma's CEO, Dror Ben-Asher, was directed to contact Tim Buchmiller at the SEC with any further questions.

RedHill Biopharma Ltd., a biopharmaceutical company, received a notification from the United States Securities and Exchange Commission (SEC) on February 14, 2024, regarding its Registration Statement on Form F-1, which was filed on February 9, 2024. The SEC informed the company that it has not reviewed and will not review the registration statement. The SEC's communication reminded RedHill Biopharma of its responsibility for the accuracy and adequacy of the disclosures in the registration statement. The SEC also pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. RedHill Biopharma's CEO, Dror Ben-Asher, was directed to contact Tim Buchmiller at the SEC with any further questions.